FibroBiologics (FBLG) Retained Earnings (2022 - 2026)

FibroBiologics (FBLG) has reported Retained Earnings for 5 consecutive years, with $67.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 47.64% year-over-year to $67.9 million; the trailing twelve-month figure through Jun 2026 stood at $67.9 million (up 47.64% YoY), and the FY2025 full-year result was $60.3 million, up 57.68% from the prior year.
• Retained Earnings advanced to $67.9 million in Q2 2026 per FBLG's latest filing, from $61.8 million in the prior quarter.
• Across five years, Retained Earnings topped out at $67.9 million in Q2 2026 and bottomed at -$32.8 million in Q1 2024.
• Historically, Retained Earnings has averaged $29.7 million across 5 years, with a median of $40.5 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Retained Earnings jumped 425.32% in 2023, then soared 44.19% in 2026.
• Over 5 years, Retained Earnings stood at -$7.9 million in 2022, then surged by 425.32% to $25.6 million in 2023, then jumped by 49.37% to $38.3 million in 2024, then jumped by 57.68% to $60.3 million in 2025, then increased by 12.59% to $67.9 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $67.9 million, $61.8 million, and $60.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.